Some prior research indicates that naltrexone, an antagonist or weak partial agonist of opioid receptors (considering dynorphin’s action through opioid K/KOR receptors), has been beneficial in managing PCOS. The gene discussed is PDYN; the disease is polycystic ovary syndrome.